CPHSP has conducted national surveillance of infants and children born to HIV-infected women using data from public health units and pediatric care centres across Canada. CPHSP recently published a detailed report of the results of their surveillance. 6 We identified 645 infants born in Ontario to HIVinfected mothers from 1996 to 2008. Women were considered to have early HIV diagnosis if: 1) the mother's date of HIV diagnosis was prior to the infant's date of birth, or 2) the mother received antiretroviral prophylaxis during pregnancy for those with unknown date of HIV diagnosis; otherwise they were considered to have late HIV diagnosis. We selected this cut-off on the basis that the second (intrapartum) and third (postpartum) components of ARP could be implemented if HIV were diagnosed prior to delivery. While this might not be as effective in preventing MTC transmission as the full three-component ARP regimen, it provided an easily defined cut-off for intervention and constituted a minimum, if not ideal, time of HIV diagnosis. We classified completeness of ARP as follows: a) complete ARP when the mother received combination antiretroviral therapy during pregnancy and intravenous ZDV during labour and the infant received a six-week course of ZDV (with or without other ARP drugs); b) incomplete ARP when appropriate ARP was not administered during one or two of these periods; c) no ARP when no ARP was given. Maternal exposure category was classified according to a mutually exclusive risk hierarchy based on the most likely source of HIV infection as follows: injection drug user (IDU), born in an HIV-endemic country, heterosexual contact other than in an HIV-endemic country, blood transfusion, clotting factors, and perinatal acquisition.
Component 2: Characterizing the modifiable factors responsible for MTC transmission
Medical charts of infants with perinatal HIV infection born from 1999 to 2008 were reviewed to obtain information on laboratory results, mother's immigration status and social history, prenatal care including ARP, adherence and breast-feeding history. Infants were classified as being HIV-infected if they had a positive HIV PCR test prior to 18 months of age or a positive HIV antibody test at age 18 months of age or later. The review of the social history of the mother was assessed for illicit drug use, commercial sex work and mental illness. Details of ARP uptake were assessed by the type and timing of drug regimens administered during pregnancy, at delivery and to the infant. We also interviewed doctors, nurses and social workers who had cared for these children for cases with incomplete charts. These interviews focused only on the areas where additional data were required, were carried out for approximately 10 of the 35 cases, and generally lasted 15-20 minutes.
Statistical analyses
Summary statistics were used to describe the characteristics of HIV-infected mothers. Differences in proportions were assessed using ² tests and Fisher's Exact Test when expected cell size was less than five. We performed multivariate logistic regression analysis to identify factors associated with late HIV diagnosis of the mother; we obtained odds ratios and 95% confidence intervals for each independent variable. The earliest period was selected as the referent for the time period variable. However, we observed strong collinearity between race/ethnicity and exposure category and, therefore, the two variables could not be included in the same model. In fact, 97% of women from the HIV-endemic category were Black and 96% of Black women were classified as HIV-endemic. Thus, the two categories capture essentially the same women. However, because we were interested in the comparisons with other races/ethnicities and other exposure categories, we analyzed the data using two independent models.
We used SAS Version 9.2 (SAS Institute, Cary, NC, USA) for significance testing and logistic regression.
RESULTS

Study population
From 1996 to 2008, 652 infants were born in Ontario to HIVinfected mothers, of whom 50 (7.7%) were HIV-infected and 595 (91.3%) were not infected; for 7 (1.1%), the HIV status of the infant was unknown. Of those with unknown HIV status, 2 died before HIV status could be determined, 1 moved away from Canada, 1 is pending and the remaining 3 were lost to follow-up. The characteristics of the women (n=645) for whom HIV status of their infants was known are presented in Table 1 . Most women were either Black (63.3%) or White (26.3%), and were born in either sub-Saharan Africa (52.4%) or Canada (29.6%). Sixty-five percent were born in an HIV-endemic country and 26.3% were otherwise infected heterosexually. The number of infants born to HIV-infected mothers increased from 23 per year in 1996-1998 to 72 per year in [2005] [2006] [2007] [2008] . The proportion of HIV-infected infants decreased from 20.0% in the former period to 2.8% in the latter period. Compared to women whose infants were not infected, mothers of HIV-infected infants were less likely to have been prescribed ARP during pregnancy (22.0% vs. 96.8%, p<0.0001) and more likely to have had a vaginal delivery (78.6% vs. 55.6%, p=0.011).
Component 1: Characterizing late HIV diagnosis among HIV-infected mothers
Among the 645 HIV-infected women, 529 (82.0%) women were diagnosed prior to the birth of the infant (including women without an HIV diagnosis date but who received ARP during pregnancy) while 85 (13.2%) had late HIV diagnosis. We were unable to determine the timing of HIV diagnosis for 31 (4.8%) women. The proportion of women who had late HIV diagnosis significantly decreased over the study period: 28.6% in 1996-1998, 23. . A higher proportion of women with injection drug use as a risk factor were diagnosed late compared to women who were born in HIV-endemic countries and women categorized as infected heterosexually (20.4%, 12.8%, and 11.0%, respectively), though the differences were not statistically significant. There was no difference in late diagnosis by race/ethnicity (White 14.8%, Black 12.3%, Asian 16.0% and other 14.7%).
The results of the two regression models are presented in Table 2 . In Model 1, late diagnosis was more frequent in non-White racial/ethnic groups compared to White but these differences were not statistically significant. Late diagnosis decreased in later study periods and was significantly lower in the last two periods. With respect to Model 2, late HIV diagnosis did not appear to vary by the mother's exposure category. After adjusting for race/ethnicity, women were less likely to have a late HIV diagnosis in the later years compared with 1996-1998, as in Model 1.
Component 2: Characterizing the modifiable factors responsible for MTC transmission
Thirty-five confirmed cases of MTC transmission of HIV were identified in Ontario from 1999 to 2008. This included 28 (80%) cases from Toronto, 4 (11%) from Hamilton and 3 (9%) from Ottawa.
Potential underlying reasons for vertical HIV transmission in these cases by maternal exposure category are presented in Figure 1 and Table 3 . Seventy-seven percent (27/35) of these mothers were diagnosed with HIV at or after delivery, 6 prior to conception and 2 during pregnancy. Seventy-one percent (25/35) were from an HIV-endemic country, 2 were IDU, 7 were infected through heterosexual contact and 1 had unknown risk factors. Thirty-four percent (11/35) of these mothers breast-fed their infants.
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Of the six mothers diagnosed with HIV prior to conception, all received either no or incomplete ARP. Of these, 4 refused to take ARP or were non-compliant and 2 failed to inform their care provider of their HIV-positive status.
Of the 2 mothers diagnosed during pregnancy, 1 was unaware of her HIV-positive status until two weeks prior to delivery and did not receive antenatal or intrapartum ARP, and 1 was diagnosed at 16 weeks gestation but initiated ARP only nine days prior to delivery.
Among the 27 mothers diagnosed at or after delivery, 5 had a prenatal HIV test, 13 no HIV test, and for 9 the history of prenatal HIV testing was unknown. Among the 5 mothers with a prenatal HIV test, 1 knew her positive HIV status at the time of delivery, 2 were tested 1-3 weeks prior to delivery but did not know their result, and 2, who had HIV-infected partners, had a negative HIV prenatal test during pregnancy (1 tested HIVnegative three months prior to delivery and for the other, the time of the HIV-negative test was unknown) and were infected subsequently. The reasons for no or unknown prenatal HIV test were: not offered (6), offered but refused (2) , no prenatal care (3), denied testing history (4), and offered but not done (1).
DISCUSSION
From 1996 to 2008, 652 infants were born in Ontario to HIVinfected mothers, of whom 50 became infected. As in previous studies, our results revealed that infants with more complete antiretroviral prophylaxis were less likely to become infected (complete ARP 1.2%, incomplete ARP 2.4%, and no ARP 67.2%). 3, 6, [8] [9] [10] [11] For Canada as a whole from 1997 to 2010, the Canadian Perinatal HIV Surveillance Network (CPHSP) found a vertical transmission rate of 1.0% among infants born to mothers who received cART, 1.6% for women who received mono-therapy or dual-therapy with nucleoside reverse transcriptase inhibitors, and 16.4% for women who received no ARP antenatally. For mothers who received antenatal cART at least four weeks before delivery, the MTC transmission rate was 0.4% compared to 9.0% when started later than four weeks before delivery. 6 In the UK and Ireland, the transmission rate was 0.8% in women receiving cART at least two weeks before delivery. 9 A key distinction between the CPHSP data and ours is that the data in the former are restricted to infants of HIV-infected women referred to a CPHSP participating site either before or during pregnancy or within three months following delivery (prospective cohort), whereas our study also included children diagnosed later. As a result, our study includes a higher proportion of cases of vertical transmission and, due to selective recruitment of HIV-positive infants, cannot be used to determine MTC transmission rates as the true denominator is not known.
The 
Potential reasons for MTC HIV transmission in Ontario, 1999-2008
Ministry of Health and Long-Term Care policy of offering HIV testing to all pregnant women in Ontario. Nevertheless, our study confirms that challenges remain. Late maternal HIV diagnosis was found in 27 of 35 (77%) vertical HIV transmission cases from 1999 to 2008. Furthermore, a substantial proportion (~7-8%) of HIV-infected women whose infants were not infected had late HIV diagnosis. This latter group is significant from a public health perspective because, while the infants of these mothers were not infected, they could well have been. Thus, our data confirm the need to improve timely HIV testing during pregnancy to further reduce vertical HIV transmission. One solution is to emphasize the role of HIV testing in women contemplating pregnancy in Ontario and to modify testing strategies so that marginalized women who do not access routine prenatal care can still be tested during pregnancy. Our study did not examine in depth the reasons many HIV-infected pregnant women were not tested, in particular whether these were related to the women themselves, their health providers or the organization of health services. With respect to women-related issues, cultural and psychological factors may be important given the sensitivity of HIV testing and the implications of a positive HIV result. Further research on the factors responsible for women not testing would be useful in helping to reduce the barriers to testing. A second category of missed opportunities relates to women tested antenatally for whom appropriate preventive interventions were nevertheless not implemented in a timely manner. This is exemplified by the two women in our study who were tested antenatally, but whose results were available only after delivery. This problem could readily be rectified through the use of a rapid point-of-care HIV test (or a standard HIV serologic test ordered on an emergency basis if the former option is not available) for women presenting at delivery without an HIV test on record. The Mother-Infant Rapid Intervention at Delivery (MIRIAD) trial found it acceptable and feasible to offer counseling and rapid HIV testing at the time of labour and delivery to women of unknown HIV status. 12, 13 Last, repeat testing of women at high risk of HIV acquisition later in gestation should be considered; this is illustrated by the two cases in our study who tested HIV-negative early in pregnancy and whose partners were known to be HIVinfected. In addition to serodiscordant couple scenarios, repeat testing might be appropriate for women who use intravenous drugs, those involved in the sex trade and those who have multiple sexual partners during pregnancy. The role of routine repeat testing for all women is less clear. A cost-effectiveness analysis in the US found that a second HIV test could prevent perinatal transmissions with a net savings to society when HIV incidence among women of childbearing age is ≥1.2 per 1000 person-years. 14 There are several limitations to our study. The CPHSP database does not include the mother's date of birth. Thus, we were unable to examine mother's age in our analyses. Due to loss to followup, the final HIV status of some infants was unknown; however, we estimate we would have missed at most only 2-3 children vertically infected with HIV in this way. We also found errors in the database, as we identified one duplicate case, one case incorrectly identified as HIV-infected, one case with incorrect birthplace of the infant, and one case which was not reported to the CPHSP; thus, there could have been other unidentified errors in the database. Furthermore, in the case review component of our study, the information about the mother's history relied primarily on notes in the infants' chart. However, we also collected such information through interviews with doctors, nurses and social workers; recall bias could have been introduced. Uptake of prenatal care, prenatal HIV testing and breast-feeding history were unknown for some cases, which could have led to inaccuracies in our results. Finally, we examined only some of the modifiable factors potentially responsible for MTC transmission; we did not, however, examine the biologic factors responsible for such transmission, such as maternal viral load and mode of delivery.
While overall HIV test uptake in Ontario has improved dramatically subsequent to the implementation of the Ontario Ministry of Health and Long-Term Care policy of universally offering HIV testing in pregnancy in Ontario, 15 significant gaps remain. The importance of offering HIV testing to all women early in gestation and to women contemplating pregnancy is paramount, as is the need for repeat HIV testing later in gestation for women at significant ongoing risk of HIV acquisition. We need to ensure all pregnant women have access to HIV testing, including those who do not (or cannot) access routine prenatal care. HIV testing should be timed to allow for early initiation of ARP. For women presenting late in gestation with unknown HIV status, rapid HIV testing is clearly warranted and could prevent some MTC transmissions. 
